New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab…
News
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
TOKYO, May 27, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today the presentation…
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
TOKYO, May 27, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that it…
Legend Capital’s Portfolio Company Feima Robotics Assists China’s 38th Antarctic Expedition with a Series of Civilian UAV Products
HONG KONG, May 27, 2022 – (ACN Newswire) – On April 26, 2022, the expedition…
GPDRR: Indonesia offers sustainable resilience to tackle disaster risk
Nusa Dua, Bali, May 27, 2022 – (ACN Newswire) – At the 2022 Global Platform…
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops…
Hiscox Harnesses CoreLogic Geocoding Technology to Assess Insurance Risks
RiskMeter provides structure-level location information when assessing a property’s exposure to natural disasters IRVINE, Calif.–(BUSINESS…
The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana
TOKYO, May 27, 2022 – (JCN Newswire) – The Ajinomoto Foundation, Sysmex Corporation, and NEC…
Hong Kong ‘ideal listing destination’ for ASEAN companies
HONG KONG, May 27, 2022 – (ACN Newswire) – Hong Kong has been named as…
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a…
NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting
– First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed…
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
PRESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO)…
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1…
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical…
SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting
– Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination…
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve…
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced…
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete…
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase…